首页> 外文期刊>Journal of drug targeting >A journey through the emergence of nanomedicines with poly(alkylcyanoacrylate) based nanoparticles
【24h】

A journey through the emergence of nanomedicines with poly(alkylcyanoacrylate) based nanoparticles

机译:通过聚(烷基氰基丙烯酸酯)基纳米粒子的纳米胺出现的旅程

获取原文
获取原文并翻译 | 示例
           

摘要

Starting in the late 1970s, the pioneering work of Patrick Couvreur gave birth to the first biodegradable nanoparticles composed of a biodegradable synthetic polymer. These nanoparticles, made of poly(alkyl-cyanoacrylate) (PACA), were the first synthetic polymer-based nanoparticulate drug carriers undergoing a phase III clinical trial so far. Analyzing the journey from the birth of PACA nanoparticles to their clinical evaluation, this paper highlights their remarkable adaptability to bypass various drug delivery challenges found on the way. At present, PACA nanoparticles include a wide range of nanoparticles that can associate drugs of different chemical nature and can be administered in vivo by different routes. The most recent technologies giving the nanoparticles customised functions could also be implemented on this family of nanoparticles. Through different examples, this paper discusses the seminal role of the PACA nanoparticles' family in the development of nanomedicines.
机译:从20世纪70年代后期开始,Patrick Couvreur的开创性工作患有由可生物降解的合成聚合物组成的第一个可生物降解的纳米颗粒。 由聚(烷基 - 氰基丙烯酸酯)(PACA)制成的这些纳米颗粒是迄今为止经历III期临床试验的第一合成聚合物的纳米颗粒药物载体。 分析从PACA纳米粒子诞生到临床评价的旅程,本文突出了绕过途中发现各种药物递送挑战的显着适应性。 目前,PACA纳米颗粒包括各种纳米颗粒,其可以将不同化学性质的药物赋予,并且可以通过不同的途径体内给药。 纳米颗粒定制功能的最新技术也可以在这家纳米颗粒上实施。 通过不同的例子,本文讨论了PACA纳米颗粒家族在纳米胺开发中的开创性作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号